Bookstaff R C, Murphy V A, Skare J A, Minnema D, Sanzgiri U, Parkinson A
The Procter & Gamble Company, Cincinnati, Ohio 45040-9462, USA.
Toxicol Appl Pharmacol. 1996 Dec;141(2):584-94. doi: 10.1006/taap.1996.0325.
The effects of doxylamine (as the succinate salt) on microsomal enzyme activity and serum thyroid hormone levels were examined in B6C3F1 mice following dietary exposure for 7 or 15 days (0, 40, 375, 750, or 1500 ppm in diet, expressed as free base doxylamine). In addition, the hepatic P450 enzyme inducer sodium phenobarbital (375 ppm, expressed as free acid phenobarbital) was used as a positive control for CYP2B induction. Exposure of mice to doxylamine produced dose-related increases in liver weight at both time points. Liver weights were also increased in the phenobarbital-treated mice. Doxylamine treatment caused a dose-dependent increase (up to 2.6-fold) in liver microsomal cytochrome P450 in both male and female mice, at both time points. Analyses of the activities of various hepatic microsomal cytochromes P450 indicated that doxylamine caused a marked induction of CYP2B enzymes. This was demonstrated by a large increase in the O-dealkylation of 7-pentoxyresorufin (up to 38-fold) and the 16beta-hydroxylation of testosterone (up to 6.9-fold), both of which are indicative of CYP2B induction. In addition, like phenobarbital, doxylamine treatment resulted in a modest induction of CYP3A and CYP2A enzymes and approximately a 50% increase in thyroxine-glucuronosyltransferase activity. Doxylamine did not appear to induce P450 enzymes in the CYP1A, CYP2E, or CYP4A enzyme subfamilies. None of the enzyme-inducing effects of doxylamine could be distinguished from those of phenobarbital. These results suggest that doxylamine is a phenobarbital-type inducer of liver microsomal cytochrome P450 in B6C3F1 mice. Exposure to either doxylamine or phenobarbital also resulted in decreases in serum thyroxine (T4) levels (approximately 80% of control) with compensatory increases in serum thyroid-stimulating hormone levels (approximately 4-fold). No clear changes in serum triiodothyronine levels were apparent. These findings are consistent with the hypothesis that doxylamine increases the activity of those hepatic enzymes involved in T4 metabolism.
在B6C3F1小鼠经口摄入多西拉敏(琥珀酸盐)7天或15天后(饲料中含量为0、40、375、750或1500 ppm,以游离碱多西拉敏计),检测其对微粒体酶活性和血清甲状腺激素水平的影响。此外,肝P450酶诱导剂苯巴比妥钠(375 ppm,以游离酸苯巴比妥计)用作CYP2B诱导的阳性对照。在两个时间点,小鼠接触多西拉敏均导致肝脏重量呈剂量相关增加。苯巴比妥处理的小鼠肝脏重量也增加。在两个时间点,多西拉敏处理均使雄性和雌性小鼠肝脏微粒体细胞色素P450呈剂量依赖性增加(高达2.6倍)。对各种肝微粒体细胞色素P450活性的分析表明,多西拉敏显著诱导了CYP2B酶。这通过7-戊氧基试卤灵O-脱烷基化(高达38倍)和睾酮16β-羟基化(高达6.9倍)大幅增加得以证明,这两者均表明CYP2B被诱导。此外,与苯巴比妥一样,多西拉敏处理导致CYP3A和CYP2A酶适度诱导,甲状腺素葡糖醛酸转移酶活性增加约50%。多西拉敏似乎未诱导CYP1A、CYP2E或CYP4A酶亚家族中的P450酶。多西拉敏的酶诱导作用与苯巴比妥的作用无法区分。这些结果表明,多西拉敏是B6C3F1小鼠肝微粒体细胞色素P450的苯巴比妥型诱导剂。接触多西拉敏或苯巴比妥还导致血清甲状腺素(T4)水平降低(约为对照的8